Cancer - Wiki-Pi

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide
DVL1 and SMAD2	dishevelled segment polarity protein 1	SMAD family member 2	disassembly of the destruction complex and recruitment of AXIN to the membrane WNT mediated activation of DVL misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN degradation of DVL negative regulation of TCF-dependent signaling by DVL-interacting proteins Signaling by Wnt Signaling by WNT in cancer PCP/CE pathway beta-catenin independent WNT signaling	Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Generic Transcription Pathway Signaling by NODAL TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by Activin TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer
DVL1 and SMAD4	dishevelled segment polarity protein 1	SMAD family member 4	disassembly of the destruction complex and recruitment of AXIN to the membrane WNT mediated activation of DVL misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN degradation of DVL negative regulation of TCF-dependent signaling by DVL-interacting proteins Signaling by Wnt Signaling by WNT in cancer PCP/CE pathway beta-catenin independent WNT signaling	Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by BMP Transcriptional regulation of pluripotent stem cells Generic Transcription Pathway Signaling by NODAL TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by Activin TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer
DVL1 and SMAD7	dishevelled segment polarity protein 1	SMAD family member 7	disassembly of the destruction complex and recruitment of AXIN to the membrane WNT mediated activation of DVL misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN degradation of DVL negative regulation of TCF-dependent signaling by DVL-interacting proteins Signaling by Wnt Signaling by WNT in cancer PCP/CE pathway beta-catenin independent WNT signaling	Loss of Function of TGFBR2 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling Loss of Function of SMAD4 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Signaling by BMP Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Loss of Function of TGFBR1 in Cancer Generic Transcription Pathway Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer SMAD4 MH2 Domain Mutants in Cancer
E2F4 and SMAD2	E2F transcription factor 4, p107/p130-binding	SMAD family member 2	Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Generic Transcription Pathway Mitotic G1-G1/S phases TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer G1 Phase Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer G0 and Early G1 Loss of Function of TGFBR1 in Cancer Cell Cycle, Mitotic Cyclin D associated events in G1 Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer	Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Generic Transcription Pathway Signaling by NODAL TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by Activin TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer
EFNB1 and MYC	ephrin-B1	v-myc avian myelocytomatosis viral oncogene homolog	EPHB-mediated forward signaling Ephrin signaling EPH-ephrin mediated repulsion of cells Axon guidance EPH-Ephrin signaling	Loss of Function of TGFBR2 in Cancer Signaling by NOTCH1 HD Domain Mutants in Cancer Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Signaling by Wnt Cyclin E associated events during G1/S transition binding of TCF/LEF:CTNNB1 to target gene promoters TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Generic Transcription Pathway RNF mutants show enhanced WNT signaling and proliferation G1/S Transition Signaling by NOTCH1 XAV939 inhibits tankyrase, stabilizing AXIN Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Mitotic G1-G1/S phases FBXW7 Mutants and NOTCH1 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Loss of Function of SMAD2/3 in Cancer Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer S Phase Cell Cycle, Mitotic Loss of Function of TGFBR1 in Cancer NOTCH1 Intracellular Domain Regulates Transcription Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex TCF dependent signaling in response to WNT Signaling by NOTCH1 PEST Domain Mutants in Cancer Cyclin A:Cdk2-associated events at S phase entry Signaling by WNT in cancer Constitutive Signaling by NOTCH1 PEST Domain Mutants SMAD4 MH2 Domain Mutants in Cancer
EGF and PIK3R2	epidermal growth factor	phosphoinositide-3-kinase, regulatory subunit 2 (beta)	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease PIP3 activates AKT signaling Platelet degranulation Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling Signaling by SCF-KIT SHC1 events in ERBB2 signaling Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants GRB2 events in ERBB2 signaling PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Response to elevated platelet cytosolic Ca2+ Innate Immune System Signaling by PDGF EGFR downregulation Signalling by NGF DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by FGFR EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR SHC1 events in EGFR signaling Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Constitutive Signaling by EGFRvIII Platelet activation, signaling and aggregation Adaptive Immune System	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Metabolism of lipids and lipoproteins Signaling by FGFR in disease Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation Interleukin receptor SHC signaling PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Interleukin-7 signaling Role of phospholipids in phagocytosis Phospholipid metabolism Fcgamma receptor (FCGR) dependent phagocytosis PI3K Cascade Signaling by PDGF DAP12 interactions GAB1 signalosome G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 G alpha (q) signalling events Signaling by EGFR GPCR downstream signaling Signaling by Interleukins TCR signaling Signaling by VEGF Signaling by Rho GTPases Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Nephrin interactions Interleukin-2 signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System G alpha (q) signalling events Downstream TCR signaling Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade VEGFA-VEGFR2 Pathway Rho GTPase cycle Synthesis of PIPs at the plasma membrane IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling Regulation of signaling by CBL Downstream signaling of activated FGFR G alpha (12/13) signalling events PI Metabolism Innate Immune System Signaling by Insulin receptor Signalling by NGF Insulin receptor signalling cascade IRS-related events Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall Signaling by FGFR IRS-mediated signalling Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Interleukin receptor SHC signaling PI3K Cascade	Sucralfate Alpha-Aminobutyric Acid
EGF and ADAM12	epidermal growth factor	ADAM metallopeptidase domain 12	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease PIP3 activates AKT signaling Platelet degranulation Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling Signaling by SCF-KIT SHC1 events in ERBB2 signaling Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants GRB2 events in ERBB2 signaling PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Response to elevated platelet cytosolic Ca2+ Innate Immune System Signaling by PDGF EGFR downregulation Signalling by NGF DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by FGFR EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR SHC1 events in EGFR signaling Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Constitutive Signaling by EGFRvIII Platelet activation, signaling and aggregation Adaptive Immune System	Signaling by EGFR Signaling by EGFR in Cancer Signaling by Ligand-Responsive EGFR Variants in Cancer Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by EGFRvIII in Cancer	Sucralfate Alpha-Aminobutyric Acid
EGFR and EPS15	epidermal growth factor receptor	epidermal growth factor receptor pathway substrate 15	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by EGFR EGFR downregulation Signaling by EGFR in Cancer Signaling by Ligand-Responsive EGFR Variants in Cancer Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by EGFRvIII in Cancer	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and STAM2	epidermal growth factor receptor	signal transducing adaptor molecule (SH3 domain and ITAM motif) 2	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by EGFR EGFR downregulation Endosomal Sorting Complex Required For Transport (ESCRT) Signaling by EGFR in Cancer Signaling by Ligand-Responsive EGFR Variants in Cancer Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by EGFRvIII in Cancer	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and ERBB4	epidermal growth factor receptor	erb-b2 receptor tyrosine kinase 4	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII		Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and EREG	epidermal growth factor receptor	epiregulin	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease PIP3 activates AKT signaling Signaling by EGFRvIII in Cancer Signaling by SCF-KIT SHC1 events in ERBB2 signaling Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation GRB2 events in ERBB2 signaling PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signaling by PDGF Signalling by NGF DAP12 interactions GAB1 signalosome Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR Nuclear signaling by ERBB4 SHC1 events in ERBB4 signaling Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and ESR1	epidermal growth factor receptor	estrogen receptor 1	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Nuclear signaling by ERBB4 Generic Transcription Pathway Nuclear Receptor transcription pathway Signaling by ERBB4	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib	Diethylstilbestrol Chlorotrianisene Conjugated Estrogens Etonogestrel Desogestrel Levonorgestrel Progesterone Raloxifene Toremifene Medroxyprogesterone Estrone Tamoxifen Estradiol Ethynodiol Diacetate Clomifene Dienestrol Fulvestrant Norgestimate Ethinyl Estradiol Melatonin Trilostane Naloxone Fluoxymesterone Estramustine Mestranol Danazol Allylestrenol Genistein Compound 19 Compound 18 Compound 4-D 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Estriol Estropipate Quinestrol Ospemifene 17-METHYL-17-ALPHA-DIHYDROEQUILENIN 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL RALOXIFENE CORE
EGFR and HIST3H3	epidermal growth factor receptor	histone cluster 3, H3	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	DNA Damage/Telomere Stress Induced Senescence Meiotic recombination Chromosome Maintenance misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Mitotic Prophase formation of the beta-catenin:TCF transactivating complex Cellular Senescence Meiotic synapsis Signaling by Wnt Cell Cycle, Mitotic M Phase Telomere Maintenance Packaging Of Telomere Ends TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Signaling by WNT in cancer Condensation of Prophase Chromosomes	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and SOCS7	epidermal growth factor receptor	suppressor of cytokine signaling 7	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII		Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and MET	epidermal growth factor receptor	MET proto-oncogene, receptor tyrosine kinase	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Axon guidance Semaphorin interactions Sema4D mediated inhibition of cell attachment and migration Sema4D in semaphorin signaling	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib	K-252a 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol 6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE Cabozantinib
EGFR and PIK3R3	epidermal growth factor receptor	phosphoinositide-3-kinase, regulatory subunit 3 (gamma)	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Metabolism of lipids and lipoproteins Signaling by FGFR in disease Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation Interleukin receptor SHC signaling PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Interleukin-7 signaling Phospholipid metabolism Signaling by PDGF DAP12 interactions GAB1 signalosome G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 G alpha (q) signalling events Signaling by EGFR Signaling by Interleukins GPCR downstream signaling Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Interleukin-2 signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System G alpha (q) signalling events Costimulation by the CD28 family PIP3 activates AKT signaling Synthesis of PIPs at the plasma membrane G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling Regulation of signaling by CBL Downstream signaling of activated FGFR G alpha (12/13) signalling events PI Metabolism Innate Immune System Signalling by NGF Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR GPVI-mediated activation cascade Interleukin receptor SHC signaling	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and NUMB	epidermal growth factor receptor	numb homolog (Drosophila)	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by NOTCH1 HD Domain Mutants in Cancer Hedgehog 'off' state Axon guidance Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Signaling by NOTCH L1CAM interactions Recycling pathway of L1 Activated NOTCH1 Transmits Signal to the Nucleus Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Hedgehog 'on' state Signaling by NOTCH1 Signaling by Hedgehog Signaling by NOTCH1 PEST Domain Mutants in Cancer Degradation of GLI1 by the proteasome Signaling by NOTCH1 in Cancer FBXW7 Mutants and NOTCH1 in Cancer	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and GAB1	epidermal growth factor receptor	GRB2-associated binding protein 1	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease PIP3 activates AKT signaling IRS-mediated signalling IGF1R signaling cascade Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling IRS-related events triggered by IGF1R PI3K/AKT activation Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR PI3K Cascade Innate Immune System Signaling by Insulin receptor Signaling by PDGF Signalling by NGF DAP12 interactions Insulin receptor signalling cascade GAB1 signalosome IRS-related events Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR IRS-mediated signalling Downstream signal transduction Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Signaling by FGFR mutants PI3K/AKT Signaling in Cancer Constitutive Signaling by EGFRvIII PI3K Cascade Adaptive Immune System	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and SOS1	epidermal growth factor receptor	son of sevenless homolog 1 (Drosophila)	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease SHC-mediated cascade FCERI mediated MAPK activation Platelet Aggregation (Plug Formation) Signaling by EGFRvIII in Cancer SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Regulation of KIT signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Interleukin receptor SHC signaling Gastrin-CREB signalling pathway via PKC and MAPK SOS-mediated signalling SHC-mediated signalling Signaling by PDGF DAP12 interactions SHC-related events triggered by IGF1R GRB2 events in EGFR signaling Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Signaling by ERBB2 Signaling by EGFR GPCR downstream signaling Signaling by Interleukins SHC1 events in ERBB4 signaling Signalling to RAS Downstream signal transduction Signaling by Rho GTPases Signaling by FGFR mutants Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling Interleukin-2 signaling Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System Signalling to ERKs Axon guidance IRS-mediated signalling IGF1R signaling cascade Rho GTPase cycle IRS-related events triggered by IGF1R EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling Activation of Rac Downstream signaling of activated FGFR G alpha (12/13) signalling events NCAM signaling for neurite out-growth Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Innate Immune System Signaling by Insulin receptor Signalling by NGF Insulin receptor signalling cascade Cell death signalling via NRAGE, NRIF and NADE SOS-mediated signalling SHC-mediated signalling Integrin alphaIIb beta3 signaling p75 NTR receptor-mediated signalling Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane GRB2:SOS provides linkage to MAPK signaling for Integrins SHC-related events Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall Signaling by FGFR SHC1 events in EGFR signaling FRS2-mediated cascade IRS-mediated signalling Signal attenuation NRAGE signals death through JNK Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) Interleukin receptor SHC signaling FCERI mediated Ca+2 mobilization Constitutive Signaling by EGFRvIII Signaling by Robo receptor	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and PRKACA	epidermal growth factor receptor	protein kinase, cAMP-dependent, catalytic, alpha	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by GPCR Ca-dependent events CaM pathway Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Metabolism of lipids and lipoproteins Integration of energy metabolism Hedgehog 'off' state Phospholipase C-mediated cascade Signaling by FGFR in disease Signaling by EGFRvIII in Cancer Regulation of PLK1 Activity at G2/M Transition PLCG1 events in ERBB2 signaling Gluconeogenesis Glucose metabolism DAP12 signaling Rap1 signalling Myoclonic epilepsy of Lafora Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis Glycogen storage diseases PKA-mediated phosphorylation of key metabolic factors Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell Recruitment of mitotic centrosome proteins and complexes Glucagon signaling in metabolic regulation Signaling by PDGF Calmodulin induced events DAP12 interactions PKA-mediated phosphorylation of CREB Opioid Signalling PKA activation Factors involved in megakaryocyte development and platelet production Aquaporin-mediated transport CREB phosphorylation through the activation of Adenylate Cyclase EGFR interacts with phospholipase C-gamma Signaling by ERBB2 PKA-mediated phosphorylation of CREB Signaling by EGFR Signaling by Interleukins Signaling by VEGF Downstream signal transduction Calmodulin induced events Signaling by EGFR in Cancer Metabolism of carbohydrates PKA activation Interleukin-3, 5 and GM-CSF signaling Mitotic G2-G2/M phases Transmission across Chemical Synapses Adaptive Immune System Organelle biogenesis and maintenance G2/M Transition VEGFA-VEGFR2 Pathway DAG and IP3 signaling CaM pathway Activation of NMDA receptor upon glutamate binding and postsynaptic events Loss of Nlp from mitotic centrosomes Downstream signaling of activated FGFR DARPP-32 events Post NMDA receptor activation events Innate Immune System PKA activation in glucagon signalling Signalling by NGF PLC beta mediated events Vasopressin regulates renal water homeostasis via Aquaporins Regulation of insulin secretion Cytokine Signaling in Immune system Assembly of the primary cilium Signaling by Ligand-Responsive EGFR Variants in Cancer Lipid digestion, mobilization, and transport NGF signalling via TRKA from the plasma membrane G-protein mediated events Signaling by Overexpressed Wild-Type EGFR in Cancer Anchoring of the basal body to the plasma membrane Cell Cycle, Mitotic Signaling by FGFR Loss of proteins required for interphase microtubule organizationÂ from the centrosome PLC-gamma1 signalling Signaling by Hedgehog Degradation of GLI1 by the proteasome Centrosome maturation GLI3 is processed to GLI3R by the proteasome Degradation of GLI2 by the proteasome	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib

Search Results for: Cancer